A Phase I/II, Open-label, Dose-escalation Study of Varlilumab (CDX-1127) in Combination with Atezolizumab (MPDL3280A, Anti-PD-L1) in Patients with Advanced Cancer
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Celldex Therapeutics, Inc.
Start Date
September 1, 2015
End Date
April 12, 2018
Administered By
Duke Cancer Institute
Awarded By
Celldex Therapeutics, Inc.
Start Date
September 1, 2015
End Date
April 12, 2018